DRMA_OUT_1 [2025-03-27 11:00:12 -0400] 2342 Bytes | 659 tokens | Cum: 659 tkns (8.24% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Dermata Therapeutics (DRMA) which is at 1.6399 up from 1.35. So, I pulled together a bunch of data for you to look over real fast. It's still early, 11:00:10 AM on Thu Mar 27, 2025 -0400. So, what's the verdict? You're the expert!

Here's the first list of news for Dermata Therapeutics:

C1 - Today 08:00AM - BREAKING: Dermata's XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints
C2 - Mar-17-25 04:16PM - Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
C3 - Mar-04-25 08:03AM - Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI Phase 3 STAR-1 Clinical Trial for Acne
C4 - Feb-25-25 07:58AM - Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
C5 - Jan-29-25 04:05PM - Dermata to Present on BioPub on January 31, 2025
C6 - Jan-23-25 04:15PM - Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
C7 - Jan-22-25 08:00AM - Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
C8 - Jan-21-25 08:00AM - Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Prior AI Reports for DRMA:

1. 2025-03-27 – Score: – – Target: – – Highs: – / – / –

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Dermata Therapeutics (DRMA)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

DRMA_OUT_3 [2025-03-27 11:00:17 -0400] 1105 Bytes | 300 tokens | Cum: 961 tkns (12.01% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**BREAKING: Dermata's XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints**
Date: Today 08:00AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/breaking-dermatas-xyngari-phase-3-trial-topline-data-meets-all-primary-endpoints-302412922.html

- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne -

- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne-

- Over 30 million acne patients seek treatment in the U.S. each year -

SAN DIEGO,March 26, 2025/PRNewswire/ --Dermata Therapeutics, Inc.(Nasdaq:DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive toplin

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DRMA_OUT_5 [2025-03-27 11:00:19 -0400] 992 Bytes | 284 tokens | Cum: 1326 tkns (16.57% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-27T14:21:41Z - Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Dermata T...
A2 - 2025-03-27T13:51:32Z - Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Dermata Therapeutics (NASDAQ:DRMA), Au...
A3 - 2025-03-27T13:02:22Z - Dermata Therapeutics Says Phase 3 STAR-1 Study Of Xyngari To Treat Acne Met Primary Goals; Stock Up...
A4 - 2025-03-27T12:35:23Z - Dermata shares rise on positive acne treatment trial results By Investing.com...
A5 - 2025-03-27T12:36:12Z - Dermata shares rise on positive acne treatment trial results By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

DRMA_OUT_7 [2025-03-27 11:00:25 -0400] 1098 Bytes | 308 tokens | Cum: 1636 tkns (20.45% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Dermata Therapeutics (NASDAQ:DRMA)**Date: 2025-03-27Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/general/biotech/25/03/44515808/nano-cap-dermata-therapeutics-unveils-positive-data-from-once-weekly-drug-study-for-acneMarkets are swinging wildly, but for Matt Maley, it's just another opportunity to trade. His clear, simple trade alerts have helped members lock in gains as high as 100% and 450%. Now, you can get his next trade signal -- completely free.

Dermata Therapeutics, Inc. DRMA stock is trading higher on Thursday.

The company, which focuses on skin diseases and aesthetic applications, released topline results from its first pivotal STAR-1 Phase 3 trial of Xyngari.

The novel, once-weekly, topical product candidate for moderate-to-

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DRMA_OUT_9 [2025-03-27 11:00:27 -0400] 920 Bytes | 293 tokens | Cum: 2007 tkns (25.09% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-24T09:27:11Z - Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
B2 - 2024-01-05T18:13:57Z - Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B3 - 2024-01-05T17:11:05Z - Dow Turns Lower; ISM Services PMI Falls In December
B4 - 2024-01-05T13:03:11Z - Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
B5 - 2023-12-18T19:46:47Z - 3 Essential Strategies for Penny Stocks Trading in 2024
B6 - 2023-11-17T14:06:00Z - Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

DRMA_OUT_11 [2025-03-27 11:00:30 -0400] 681 Bytes | 187 tokens | Cum: 2196 tkns (27.45% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/07/39925905/why-enphase-energy-shares-are-trading-higher-here-are-20-stocks-moving-premarketEnphase Energy reported mixed Q2 results, leading to a rise in its stock price. Several other companies saw significant pre-market movements, both positive and negative, due to various news and earnings reports.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DRMA_OUT_13 [2025-03-27 11:00:32 -0400] 1134 Bytes | 321 tokens | Cum: 2555 tkns (31.94% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 8-K Item 7.01. Regulation FD Disclosure.

On March 27, 2025, Dermata Therapeutics, Inc. (the Company) issued a press release announcing topline results from the Companys first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of XYNGARI, a novel, once-weekly, topi...

S2 - 2025-03-27 8-K Item 7.01. Regulation FD Disclosure.

On March 27, 2025, Dermata Therapeutics, Inc. (the Company) issued a press release announcing topline results from the Companys first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of XYNGARI, a novel, once-weekly, topi...

S3 - 2025-03-17 8-K Item 2.02. Results of Oper and Fin Cond.

On March 17, 2025, Dermata Therapeutics, Inc. (the Company) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2024. A copy of the press relea...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

DRMA_OUT_15 [2025-03-27 11:00:35 -0400] 1098 Bytes | 281 tokens | Cum: 2838 tkns (35.48% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 7.01. Regulation FD Disclosure.

On March 27, 2025, Dermata Therapeutics, Inc. (the Company) issued a press release announcing topline results from the Companys first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of XYNGARI, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933,

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DRMA_OUT_17 [2025-03-27 11:00:42 -0400] 315 Bytes | 95 tokens | Cum: 2935 tkns (36.69% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DRMA_OUT_19 [2025-03-27 11:00:56 -0400] 5798 Bytes | 1598 tokens | Cum: 4628 tkns (57.85% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+----------------------+-----------------------+----------------------+----------------------+
| Volume: 64,834,402 | SMA50: 34.75% | Market Cap: 8.90M | Option/Short: No / No | Sales past 5Y: 0.00% | Sales Surprise: - |
+---------------------+----------------------+----------------------+-----------------------+----------------------+----------------------+
| Avg Volume: 341.05K | SMA200: 2.64% | Shs Outstand: 5.43M | Short Float: 4.73% | Employees: 8 | EPS Surprise: 10.67% |
+---------------------+----------------------+----------------------+-----------------------+----------------------+----------------------+
| Rel Volume: 825.61 | Perf Week: 38.98% | Shs Float: 3.99M | Short Ratio: 0.55 | Debt/Eq: 0.00 | P/E: - |
+---------------------+----------------------+----------------------+-----------------------+----------------------+----------------------+
| RSI (14): 77.09 | Perf Month: 37.82% | Inst Own: 0.84% | Short Interest: 0.19M | Sales Y/Y TTM: - | Earnings: Mar 17 AMC |
+---------------------+----------------------+----------------------+-----------------------+----------------------+----------------------+
| ATR (14): 0.16 | Perf Quarter: 33.33% | Insider Own: 26.53% | Beta: 0.49 | ROE: -310.44% | |
+---------------------+----------------------+----------------------+-----------------------+----------------------+----------------------+
| SMA20: 33.18% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -787.11% | |
+---------------------+----------------------+----------------------+-----------------------+----------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Dermata Therapeutics, Inc. (DRMA) by HALE DAVID F (Unknown Title) on 2025-01-21
- Common Stock: 78741 shares at $N/A (I) Footnote: The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- Warrant (Right to Buy): 78741 shares at $N/A (I) Footnote: The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Inside Trans: Dermata Therapeutics, Inc. (DRMA) by PROEHL GERALD T (President, CEO and Chairman) on 2025-01-21
- Common Stock: 787402 shares at $N/A (I) Footnote: The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- Warrant (Right to Buy): 787402 shares at $N/A (I) Footnote: The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -12287461.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.59
Average Volume: 3056701.13
30-Day High: 1.59
30-Day Low: 1.0992

[Detailed Financials: TTM 2024]
- Total Assets: $3,533,888.0
- Total Liabilities: $1,972,794.0
- Total Equity: $1,561,094.0
- Current Assets: $3,533,888.0
- Current Liabilities: $1,972,794.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -8.03

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $11,100,000.0

[Detailed Financials: FY 2024]
- Total Assets: $3,533,888.0
- Total Liabilities: $1,972,794.0
- Total Equity: $1,561,094.0
- Current Assets: $3,533,888.0
- Current Liabilities: $1,972,794.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -8.03

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $11,100,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

DRMA_OUT_21 [2025-03-27 11:01:01 -0400] 676 Bytes | 167 tokens | Cum: 5032 tkns (62.90% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

DRMA_IN_23 [2025-03-27 11:01:01 -0400] 126 Bytes | 29 tokens | Cum: 5148 tkns (64.35% of 8k)
==========================================================================

====================================
[2025-03-27 08:01:01] # Analysis Completed
Elapsed Time: 51.82 seconds